144 related articles for article (PubMed ID: 12935804)
1. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance.
Morrica A; Nardini C; Falbo A; Bailey AC; Bucci E
Biologicals; 2003 Sep; 31(3):165-73. PubMed ID: 12935804
[TBL] [Abstract][Full Text] [Related]
2. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
3. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
Biescas H; Gensana M; Fernández J; Ristol P; Massot M; Watson E; Vericat F
Haematologica; 1998 Apr; 83(4):305-11. PubMed ID: 9592979
[TBL] [Abstract][Full Text] [Related]
4. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
[TBL] [Abstract][Full Text] [Related]
5. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
6. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
7. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
[TBL] [Abstract][Full Text] [Related]
9. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
10. A highly purified antithrombin III concentrate prepared from human plasma fraction IV-1 by affinity chromatography.
Lebing WR; Hammond DJ; Wydick JE; Baumbach GA
Vox Sang; 1994; 67(2):117-24. PubMed ID: 7801599
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
[TBL] [Abstract][Full Text] [Related]
12. Iodine-mediated inactivation of lipid- and nonlipid-enveloped viruses in human antithrombin III concentrate.
Highsmith F; Xue H; Chen X; Benade L; Owens J; Shanbrom E; Drohan W
Blood; 1995 Jul; 86(2):791-6. PubMed ID: 7606009
[TBL] [Abstract][Full Text] [Related]
13. Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb) for viral inactivation.
Azari M; Ebeling A; Baker R; Burhop K; Camacho T; Estep T; Guzder S; Marshall T; Rohn K; Sarajari R
Artif Cells Blood Substit Immobil Biotechnol; 1998 Nov; 26(5-6):577-82. PubMed ID: 9844723
[TBL] [Abstract][Full Text] [Related]
14. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
[TBL] [Abstract][Full Text] [Related]
15. Viral safety of C1-inhibitor NF.
Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
[TBL] [Abstract][Full Text] [Related]
16. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
[TBL] [Abstract][Full Text] [Related]
17. Large-scale production and properties of human plasma-derived activated Factor VII concentrate.
Tomokiyo K; Yano H; Imamura M; Nakano Y; Nakagaki T; Ogata Y; Terano T; Miyamoto S; Funatsu A
Vox Sang; 2003 Jan; 84(1):54-64. PubMed ID: 12542734
[TBL] [Abstract][Full Text] [Related]
18. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
Gugerell A; Sorgenfrey D; Laggner M; Raimann J; Peterbauer A; Bormann D; Suessner S; Gabriel C; Moser B; Ostler T; Mildner M; Ankersmit HJ
Blood Transfus; 2020 Jan; 18(1):30-39. PubMed ID: 30865581
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
20. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
